Roman Butler Fullerton & Co. Buys 23,783 Shares of Pfizer Inc. (NYSE:PFE)

Roman Butler Fullerton & Co. boosted its holdings in shares of Pfizer Inc. (NYSE:PFE) by 43.3% in the 4th quarter, Holdings Channel reports. The firm owned 78,734 shares of the biopharmaceutical company’s stock after buying an additional 23,783 shares during the period. Pfizer accounts for about 0.8% of Roman Butler Fullerton & Co.’s holdings, making the stock its 29th largest position. Roman Butler Fullerton & Co.’s holdings in Pfizer were worth $2,163,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Worth Asset Management LLC acquired a new position in shares of Pfizer during the first quarter worth $29,000. Briaud Financial Planning Inc acquired a new stake in Pfizer in the third quarter valued at $30,000. GoalVest Advisory LLC increased its holdings in Pfizer by 304.9% in the fourth quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company’s stock valued at $31,000 after purchasing an additional 811 shares during the period. Mizuho Securities Co. Ltd. acquired a new stake in Pfizer in the third quarter valued at $34,000. Finally, VisionPoint Advisory Group LLC increased its holdings in Pfizer by 52,350.0% in the third quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock valued at $35,000 after purchasing an additional 1,047 shares during the period. 68.36% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of brokerages have commented on PFE. Guggenheim began coverage on shares of Pfizer in a research report on Friday, February 23rd. They set a “buy” rating and a $36.00 price target on the stock. TD Cowen cut shares of Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price target on the stock. in a research report on Thursday, January 4th. Argus cut shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $45.00 price target on shares of Pfizer in a research report on Monday. Twelve equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $36.88.

Pfizer Stock Performance

Shares of PFE stock traded down $0.07 during trading hours on Thursday, hitting $25.35. 4,979,347 shares of the company were exchanged, compared to its average volume of 42,050,078. The firm has a fifty day simple moving average of $27.19 and a 200 day simple moving average of $28.76. The company has a current ratio of 0.91, a quick ratio of 0.69 and a debt-to-equity ratio of 0.69. Pfizer Inc. has a 52-week low of $25.26 and a 52-week high of $40.56. The stock has a market capitalization of $143.55 billion, a price-to-earnings ratio of 70.57, a P/E/G ratio of 1.16 and a beta of 0.61.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.29. Pfizer had a net margin of 3.62% and a return on equity of 10.88%. The business had revenue of $14.25 billion during the quarter, compared to analyst estimates of $14.37 billion. During the same period in the previous year, the business earned $1.14 EPS. Pfizer’s revenue was down 41.3% compared to the same quarter last year. Research analysts predict that Pfizer Inc. will post 2.24 earnings per share for the current fiscal year.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.